Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 106

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 106
---
 of 2023 and additional expenses
associated with the BCA.

<div align='center'>66</div>

Finance income (expense)

Finance expenses decreased
by approximately $6,070 thousand, or 275.8%, to approximately $3,869 thousand finance income for the year ended December 31, 2024, compared
to approximately $2,201 thousand finance expense for the year ended December 31, 2023. The decrease resulted mainly from change in fair
value of convertible notes and a change in fair value of warrant liability.

Net income (loss)

Net loss decreased by approximately
$8,933 thousand to approximately $4,801 thousand net income for the year ended December 31, 2024, compared to $4,132 thousand net loss
for the year ended December 31, 2023. The decrease was mainly the result of an increase in our finance income and from the Horizon 2020
Grant.

Critical Accounting Policies and Estimates

We describe our significant
accounting policies and estimates in Note 2 to our annual financial statements contained elsewhere in this prospectus. We believe
that these accounting policies and estimates are critical in order to fully understand and evaluate our financial condition and results
of operations.

We prepare our financial
statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).

In preparing these financial
statements, management has made judgments, estimates and assumptions that affect the application of our accounting policies and the reported
amounts recognized in the financial statements. On a periodic basis, we evaluate our estimates, including those related to share-based
compensation and derivatives. We base our estimates on historical experience, authoritative pronouncements and various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.

We evaluated the convertible
notes in accordance with ASC 470 “Debt”, or ASC 470. The proceeds from the issuance of notes or loan with conversion features
that are determined to not be beneficial are allocated entirely to liabilities in accordance with ASC 470. As part of the convertible
loan fair value measurement, we use significant estimates which include discount rate, probabilities for the occurrence of an IPO, exit
event and failure and expected convertible notes terms.

Additionally, we evaluated
the outstanding warrants in accordance with ASC 815 “Derivatives and Hedging - Contracts in Entity’s Own Equity”, or
ASC 815. Warrants which are freestanding instruments, are considered a liability and measured at